Nvidia斥半億美元投資藥物研發AI模型訓練 Recursion爆升逾70%
晶片龍頭Nvidia(NVDA.US)周三(12日)表示,將投資5,000萬美元加速生物技術公司Recursion(RXRX.US)人工智能模型訓練,以用於藥物研發,令Recursion股價爆升約73%。Nvidia升逾2%。
Recursion將使用其超過23,000TB的生物和化學數據於Nvidia的雲平台上訓練AI模型。其後Nvidia將可使用通過生成式人工智能雲服務BioNeMo,將生物化學AI模型授權予其他生物技術公司。
Recursion擁有Recursion OS平台,令製藥商訪問設計和開發療法所需的數據,Recursion的顧問包括AI先驅Yoshua Bengio。
目前尚未清楚Nvidia會否入股Recursion。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.